Advanced Search
LU Chi, LU Hongda, LEI Zhang, YU Jing, HUANG Ting, LI Li. Clinical Analysis of Salvage Radiotherapy for Local Recurrent Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 395-399. DOI: 10.3971/j.issn.1000-8578.2014.04.025
Citation: LU Chi, LU Hongda, LEI Zhang, YU Jing, HUANG Ting, LI Li. Clinical Analysis of Salvage Radiotherapy for Local Recurrent Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(04): 395-399. DOI: 10.3971/j.issn.1000-8578.2014.04.025

Clinical Analysis of Salvage Radiotherapy for Local Recurrent Esophageal Carcinoma

More Information
  • Received Date: April 26, 2013
  • Revised Date: September 28, 2013
  • Objective To analyze the long-term efficacy and toxicity of salvage radiotherapy for local recurrent esophageal carcinoma. Methods One hundred and sixteen patients with local recurrent esophageal carcinoma underwent salvage radiotherapy. Radiotherapy technology was conventional twodimensional planning(15%) and conformal three-dimensional planning(85%). Sixty-six patients were treated with concurrent chemoradiotherapy. Salvage radio(chemo)therapy was carried out with a median dose of 45 Gy. Results Median follow-up time for surviving patients from the start of R(C)T was 38 months (range 10-105 months). Relief of symptoms was 76%. The median survival time was 14 months and the median recurrence-free interval was 8 months. The survival rates at 1, 2, and 3 years were 56.9%,29.3% and 14.7%, respectively. The recurrence-free survival rates at 1, 2, and 3 years were 43.1%, 20.6% and 10.4%, respectively. Nine patients lived more than 5 years(range 61-105 months). The median survival time and the survival rates at 3 years were 9 months and 5% in salvage radiotherapy dose??45 Gy group, while 19 months and 24% in those who received dose≥45 Gy(P=0.001). The median survival time and the survival rates at 3 years was 4 months and 10% in patients who used conventional two-dimensional planning, while 15 months and 19% in those who used conformal three-dimensional planning (P=0.03). Radiation esophagitis and radiodermatitis at grade 2 and 3 were most common acute toxicities. No treatment-related death was observed. Conclusion Salvage radio(chemo)therapy is effective for local recurrent esophageal carcinoma, especially for relief of symptoms. Toxicity is in an acceptable range. The outcome of local recurrent esophageal carcinoma is poor, however, longer survival after radio(chemo)therapy might be possible, even could reach long-term survival. A salvage radiation dose≥45Gy and conformal RT are associated with a better prognosis.
  • [1]
    Schmidberger H, Hess CF, Becker H, et al. Ösophagus[M]//Bamberg M, Molls M, Sack H, et al. Radioonkologie 2nd ed. German: Zuckschwerdt,2009:317-44.
    [2]
    Wolf M, Zehentmayr F, Niyazi M, et al. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer[J]. Strahlenther Onkol ,2010,186(7):374-81.
    [3]
    Law SY, Fok M, Wong J. Pat tern of recur rence af ter oesophageal resection for cancer: clinical implications[J]. Br J Surg,1996,83(1):107-11.
    [4]
    Yano M, Takachi K, Doki Y, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer[J]. Dis Esophagus,2006,19(2):73-7.
    [5]
    Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors[J]. Jpn J Clin Oncol,2007,37(12):918-23.
    [6]
    Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection[J]. Ann Surg Oncol,2008,15(9):2451-7.
    [7]
    Maruyama K, Motoyama S, Anbai A, et al. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma: clinical effi cacy of radiotherapy[J]. Dis Esophagus,20 11 ,24(3):166-71.
    [8]
    Urba SG, Chansky K, VanVeldhuizen PJ, et al. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a southwest oncolgy group study[J]. Invest New Drugs,2004, 22(1):91-7.
    [9]
    Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus[J]. N Engl J Med,1992,326(24):1593-8.
    [10]
    Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5- fl uorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516)[J]. Jpn J Clin Oncol,2004, 34(10):615-9.
    [11]
    Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combinedmodality therapy for esophageal cancer: high-dose versus standarddose radiation therapy[J]. J Clin Oncol,2002, 20(5):1167-74.
    [12]
    Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113[J]. J Clin Oncol,2008,26(28):4551-6.
    [13]
    Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol,2005,23(10):2310-7.
    [14]
    Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis[J]. Gut,2004,53(7):925-30.
    [15]
    Jingu K, Nemoto K, Matsushita H, et al. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5- fluorouracil for postoperative locoregional recurrent esophageal cancer[J]. BMC Cancer,2006,6:50.
    [16]
    Nishimura Y, Koike R, Nakamatsu K, et al. Concurrent chemoradiotherapy with protracted infusion of 5-FU and cisplatin for postoperative recurrent or residual esophageal cancer[J]. Jpn J Clin Oncol,2003,33(7):341-5.
    [17]
    Nemoto K, Matsushita H, Ogawa Y, et al. Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5- fl uorouracil for untreated and recurrent esophageal cancer[J]. Am J Clin Oncol,2003,26(1):46-9.
    [18]
    Koide N, Hiraguri M, Nishio A, et al. Ulcer in the gastric tube for esophageal replacement: a comparison of 12 esophageal cancer patients with or without postoperative radiotherapy[J]. J Gastroenterol Hepatol,2001,16(2):137-41.
    [19]
    Zhang J, Peng F, Li N, et al. Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer[J]. Radiat Oncol,2012,7:93.
    [20]
    Jia L,Wang RB,Yu JM, et al. Secondary radiotherapy for recurrent esophageal carcinoma after radical radiotherapy in 32 patients[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi,2006,13(11):863-4. [贾丽,王仁 本,于金明,等.食管癌放疗后复发的再放疗32例疗效观察[J].中华 肿瘤防治杂志,2006,13(11):863-4.]
    [21]
    Shen WB,Zhu SC,Wan J, et al. Three-dimensional conformal radiotherapy for loco-regionally recurrent esophageal cancer after initial radiotherapy[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 20 10,2(4):111-4. [沈文斌,祝淑钗,万钧,等. 42例放疗后复发食管癌三 维适形放疗的疗效分析[J]. 中华放射肿瘤学杂志,2010,19(2):111-4.]
    [22]
    Yamashita H, Nakagawa K, Tago M, et al. Salvage radiotherapy for postoperative loco-regional recurrence of esophageal cancer[J]. Dis Esophagus,2005,18(4):215-20.
    [23]
    Baxi SH, Burmeister B, Harvey JA, et al. Salvage defi nitive chemoradiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review[J]. J Med Imaging Radiat Oncol,2008,52(6):583-7.
  • Related Articles

    [1]CHEN Lijun, CHEN Jingqi, ZENG Bohang. Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2016, 43(9): 774-778. DOI: 10.3971/j.issn.1000-8578.2016.09.009
    [2]LI Wen, FENG Yanlin. Valuation of SUVmax, Ki-67, p53 and EGFR in Predicting Effect of Neoadjuvant Chemotherapy on Triple-negative Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 45-47. DOI: 10.3971/j.issn.1000-8578.2016.01.010
    [3]YAN Su, LI Bin, MA Xuxiang, MA Yingcai, XIONG Yuanzhi, GUO Xinjian, MA Yubin, YU Pengjie, WU Junqi, XIE Dawei, ZHAO Junhui, WU Huixian. Clinicopathological Characteristics of Young Gastric Cancer Patients in Hehuang Valley[J]. Cancer Research on Prevention and Treatment, 2015, 42(05): 502-505. DOI: 10.3971/j.issn.1000-8578.2015.05.018
    [4]ZHANG Cui-cui, WANG Jing, LI Kai. Characteristics and Prognostic Analysis of 60 Young Patients with Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 274-277. DOI: 10.3971/j.issn.1000-8578.2011.03.009
    [5]LIANG Xu-dong, SHI Xiao-feng, JIA Zong-qi. Detection andSignificance of PTEN, NFκB andKi-67 in Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 326-629. DOI: 10.3971/j.issn.1000-8578.2010.03.023
    [6]ZHONG Wei-ming, MA Li-ping, CAI Yong-lin, LIANG Wei, CHEN Wan-sheng, HUANG Zhuo, YU Hong, TAN Bi-fang. Relationship between Expression of Ki-67 Protein and Radiosensitivity of Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 195-196. DOI: 10.3971/j.issn.1000-8578.2010.02.019
    [7]SHI Guo-qing, ZHAO Kui, WANG Hong, LIU Mo-rong. Expression of Gastrin and Ki-67 in Gastric Cancer and Precancerous Pesions[J]. Cancer Research on Prevention and Treatment, 2009, 36(09): 756-758. DOI: 10.3971/j.issn.1000-8578.2009.09.011
    [8]HE Yan-jiao, LIU Zhao-xia, LI Hong-li, YU Jin, LI Guang. Expression and Significance of E-cadherin and Ki-67 in Colorectal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2007, 34(09): 699-702. DOI: 10.3971/j.issn.1000-8578.2529
    [9]ZHENG Lei, HAN Yue-wu. Antisense Oligodeoxyribonucleotide Target Ki-67 Inhibits Proliferation of Human Hepatocellucar Carcinoma Cell HEPG-7402 in Vitro[J]. Cancer Research on Prevention and Treatment, 2006, 33(12): 862-864. DOI: 10.3971/j.issn.1000-8578.354
    [10]DENG Jie, CAO Dun-wen, LIU Ming-qiu, ZHU Run-qing, CHEN Hong-lei, CHEN Dao-ying, WANG Ji-e. Expression of p73, PTEN and Ki-67 Proteins in Endometrioid Adenocarcinoma and Their Significance[J]. Cancer Research on Prevention and Treatment, 2006, 33(11): 811-813. DOI: 10.3971/j.issn.1000-8578.374

Catalog

    Article views (1282) PDF downloads (514) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return